VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q29840162  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000032.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q29840162‏
035 ‎‡a  (OCoLC)Q29840162‏
100 0 ‎‡a  Margreet Bakker‏ ‎‡9  sl‏
375 ‎‡a  2‏ ‎‡2  iso5218‏
400 0 ‎‡a  Margreet Bakker‏ ‎‡c  researcher‏ ‎‡9  en‏
400 0 ‎‡a  Margreet Bakker‏ ‎‡c  onderzoeker‏ ‎‡9  nl‏
400 0 ‎‡a  Margreet Bakker‏ ‎‡c  investigadora‏ ‎‡9  es‏
400 0 ‎‡a  Margreet Bakker‏ ‎‡c  investigadora‏ ‎‡9  ast‏
670 ‎‡a  Author's A highly virulent variant of HIV-1 circulating in the Netherlands‏
670 ‎‡a  Author's A Novel Astrovirus-Like RNA Virus Detected in Human Stool‏
670 ‎‡a  Author's A novel genus in the order Picornavirales detected in human stool‏
670 ‎‡a  Author's Absence of seroreversion in 80 HAART-treated HIV-1 seropositive patients with at least five-years undetectable plasma HIV-1 viral load‏
670 ‎‡a  Author's Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector‏
670 ‎‡a  Author's Altered dynamics and differential infection profiles of lymphoid and myeloid cell subsets during acute and chronic HIV-1 infection‏
670 ‎‡a  Author's artikull shkencor i botuar në vitin 2022‏
670 ‎‡a  Author's Association between gp120 envelope V1V2 and V4V5 variable loop profiles in a defined HIV-1 transmission cluster‏
670 ‎‡a  Author's Autologous antibody capture to enrich immunogenic viruses for viral discovery‏
670 ‎‡a  Author's Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation‏
670 ‎‡a  Author's CD32+CD4+ T Cells Are Highly Enriched for HIV DNA and Can Support Transcriptional Latency‏
670 ‎‡a  Author's Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART‏
670 ‎‡a  Author's Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome‏
670 ‎‡a  Author's Characterization of an HIV-1 group M variant that is distinct from the known subtypes‏
670 ‎‡a  Author's Codon and amino acid usage in retroviral genomes is consistent with virus-specific nucleotide pressure‏
670 ‎‡a  Author's Correction: Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe‏
670 ‎‡a  Author's Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathway‏
670 ‎‡a  Author's Differences in HIV Type 1 RNA Plasma Load Profile of Closely Related Cocirculating Ethiopian Subtype C Strains: C and C′‏
670 ‎‡a  Author's Easy and Accurate Reconstruction of Whole HIV Genomes from Short-Read Sequence Data‏
670 ‎‡a  Author's From clinical sample to complete genome: Comparing methods for the extraction of HIV-1 RNA for high-throughput deep sequencing‏
670 ‎‡a  Author's Has the rate of CD4 cell count decline before initiation of antiretroviral therapy changed over the course of the Dutch HIV epidemic among MSM?‏
670 ‎‡a  Author's High Current CD4+ T Cell Count Predicts Suboptimal Adherence to Antiretroviral Therapy‏
670 ‎‡a  Author's High prevalence of hepatitis B virus dual infection with genotypes A and G in HIV-1 infected men in Amsterdam, the Netherlands, during 2000-2011‏
670 ‎‡a  Author's Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA.‏
670 ‎‡a  Author's HIV-1 dual infection is associated with faster CD4+ T-cell decline in a cohort of men with primary HIV infection‏
670 ‎‡a  Author's HIV-1 dual infection is associated with faster CD4+T cell decline in a cohort of men with primary HIV infection.‏
670 ‎‡a  Author's HIV RNA levels in transmission sources only weakly predict plasma viral load in recipients‏
670 ‎‡a  Author's Human immunodeficiency virus type 1 gp120 envelope characteristics associated with disease progression differ in family members infected with genetically similar viruses‏
670 ‎‡a  Author's Identification of a new genotype of Torque Teno Mini virus‏
670 ‎‡a  Author's Identification of alternative amino acid substitutions in drug-resistant variants of the HIV-1 reverse transcriptase‏
670 ‎‡a  Author's Incidence of human immunodeficiency virus type 1 dual infections in Amsterdam, The Netherlands, during 2003-2007.‏
670 ‎‡a  Author's Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase‏
670 ‎‡a  Author's Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands‏
670 ‎‡a  Author's Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users‏
670 ‎‡a  Author's Modest deviations from optimal adherence to antiretroviral therapy promote residual HIV-1 replication in the absence of virological rebound in plasma.‏
670 ‎‡a  Author's Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma‏
670 ‎‡a  Author's Multiple transmissions of a stable human leucocyte antigen-B27 cytotoxic T-cell-escape strain of HIV-1 in The Netherlands‏
670 ‎‡a  Author's Novel replication-incompetent vector derived from adenovirus type 11‏
670 ‎‡a  Author's Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.‏
670 ‎‡a  Author's Performance of VIDISCA-454 in feces-suspensions and serum‏
670 ‎‡a  Author's Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals‏
670 ‎‡a  Author's Routine HIV-1 genotyping as a tool to identify dual infections‏
670 ‎‡a  Author's Steady increase in cellular HIV-1 load during the asymptomatic phase of untreated infection despite stable plasma viremia‏
670 ‎‡a  Author's Survey of the temporal changes in HIV-1 replicative fitness in the Amsterdam Cohort‏
670 ‎‡a  Author's The evolution of subtype B HIV-1 tat in the Netherlands during 1985-2012.‏
670 ‎‡a  Author's Translational HIV-1 research: from routine diagnostics to new virology insights in Amsterdam, the Netherlands during 1983-2013‏
670 ‎‡a  Author's Transmission of risk-group specific HIV-1 strains among Dutch drug users for more than 20 years and their replacement by nonspecific strains after switching to low-harm drug practices‏
670 ‎‡a  Author's Transmission of two distinct HIV type 1 strains to an individual that were harbored for many years by another‏
670 ‎‡a  Author's Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe‏
670 ‎‡a  Author's Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands‏
670 ‎‡a  Author's Widespread hepatitis B virus genotype G (HBV-G) infection during the early years of the HIV epidemic in the Netherlands among men who have sex with men‏
912 ‎‡a  artikullshkencor1botuarnevitin‏ ‎‡A  artikull shkencor i botuar në vitin 2022‏ ‎‡9  1‏
919 ‎‡a  codonandaminoacidusageinretroviralgenomesisconsistentwithvirusspecificnucleotidepressure‏ ‎‡A  Codon and amino acid usage in retroviral genomes is consistent with virus-specific nucleotide pressure‏ ‎‡9  1‏
919 ‎‡a  characterizationofanhiv1group1000variantthatisdistinctfromtheknownsubtypes‏ ‎‡A  Characterization of an HIV-1 group M variant that is distinct from the known subtypes‏ ‎‡9  1‏
919 ‎‡a  cellularlevelsofhivunsplicedrnafrompatientsoncombinationantiretroviraltherapywithundetectableplasmaviremiapredictthetherapyoutcome‏ ‎‡A  Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome‏ ‎‡9  1‏
919 ‎‡a  cellassociatedhiv1rnapredictsviralreboundanddiseaseprogressionafterdiscontinuationoftemporaryearlyart‏ ‎‡A  Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART‏ ‎‡9  1‏
919 ‎‡a  cd32+cd4+tcellsarehighlyenrichedforhivdnaandcansupporttranscriptionallatency‏ ‎‡A  CD32+CD4+ T Cells Are Highly Enriched for HIV DNA and Can Support Transcriptional Latency‏ ‎‡9  1‏
919 ‎‡a  broadcrosscladetcellresponsestogaginindividualsinfectedwithhumanimmunodeficiencyvirustype1nonbcladesatogimportanceofhlaanchorresidueconservation‏ ‎‡A  Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation‏ ‎‡9  1‏
919 ‎‡a  autologousantibodycapturetoenrichimmunogenicvirusesforviraldiscovery‏ ‎‡A  Autologous antibody capture to enrich immunogenic viruses for viral discovery‏ ‎‡9  1‏
919 ‎‡a  associationbetweengp120envelopev1v2andv4v5variableloopprofilesinadefinedhiv1transmissioncluster‏ ‎‡A  Association between gp120 envelope V1V2 and V4V5 variable loop profiles in a defined HIV-1 transmission cluster‏ ‎‡9  1‏
919 ‎‡a  altereddynamicsanddifferentialinfectionprofilesoflymphoidandmyeloidcellsubsetsduringacuteandchronichiv1infection‏ ‎‡A  Altered dynamics and differential infection profiles of lymphoid and myeloid cell subsets during acute and chronic HIV-1 infection‏ ‎‡9  1‏
919 ‎‡a  adenovirustypes5and35seroprevalenceinaidsriskgroupssupportstype35asavaccinevector‏ ‎‡A  Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector‏ ‎‡9  1‏
919 ‎‡a  absenceofseroreversionin80haarttreatedhiv1seropositivepatientswithatleast5yearsundetectableplasmahiv1viralload‏ ‎‡A  Absence of seroreversion in 80 HAART-treated HIV-1 seropositive patients with at least five-years undetectable plasma HIV-1 viral load‏ ‎‡9  1‏
919 ‎‡a  novelgenusintheorderpicornaviralesdetectedinhumanstool‏ ‎‡A  A novel genus in the order Picornavirales detected in human stool‏ ‎‡9  1‏
919 ‎‡a  novelastroviruslikernavirusdetectedinhumanstool‏ ‎‡A  A Novel Astrovirus-Like RNA Virus Detected in Human Stool‏ ‎‡9  1‏
919 ‎‡a  highlyvirulentvariantofhiv1circulatinginthenetherlands‏ ‎‡A  A highly virulent variant of HIV-1 circulating in the Netherlands‏ ‎‡9  1‏
919 ‎‡a  widespreadhepatitisbvirusgenotypeghbvginfectionduringtheearlyyearsofthehivepidemicinthenetherlandsamongmenwhohavesexwithmen‏ ‎‡A  Widespread hepatitis B virus genotype G (HBV-G) infection during the early years of the HIV epidemic in the Netherlands among men who have sex with men‏ ‎‡9  1‏
919 ‎‡a  viralloadlevelsmeasuredatsetpointhaverisenoverthelastdecadeofthehivepidemicinthenetherlands‏ ‎‡A  Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands‏ ‎‡9  1‏
919 ‎‡a  viralgeneticvariationaccountsfora3ofvariabilityinhiv1setpointviralloadineurope‏ ‎‡A  Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe‏ ‎‡9  1‏
919 ‎‡a  transmissionof2distincthivtype1strainstoanindividualthatwereharboredformanyyearsbyanother‏ ‎‡A  Transmission of two distinct HIV type 1 strains to an individual that were harbored for many years by another‏ ‎‡9  1‏
919 ‎‡a  transmissionofriskgroupspecifichiv1strainsamongdutchdrugusersformorethan20yearsandtheirreplacementbynonspecificstrainsafterswitchingtolowharmdrugpractices‏ ‎‡A  Transmission of risk-group specific HIV-1 strains among Dutch drug users for more than 20 years and their replacement by nonspecific strains after switching to low-harm drug practices‏ ‎‡9  1‏
919 ‎‡a  translationalhiv1researchfromroutinediagnosticstonewvirologyinsightsinamsterdamthenetherlandsduring1983‏ ‎‡A  Translational HIV-1 research: from routine diagnostics to new virology insights in Amsterdam, the Netherlands during 1983-2013‏ ‎‡9  1‏
919 ‎‡a  evolutionofsubtypebhiv1tatinthenetherlandsduring1985‏ ‎‡A  The evolution of subtype B HIV-1 tat in the Netherlands during 1985-2012.‏ ‎‡9  1‏
919 ‎‡a  surveyofthetemporalchangesinhiv1replicativefitnessintheamsterdamcohort‏ ‎‡A  Survey of the temporal changes in HIV-1 replicative fitness in the Amsterdam Cohort‏ ‎‡9  1‏
919 ‎‡a  steadyincreaseincellularhiv1loadduringtheasymptomaticphaseofuntreatedinfectiondespitestableplasmaviremia‏ ‎‡A  Steady increase in cellular HIV-1 load during the asymptomatic phase of untreated infection despite stable plasma viremia‏ ‎‡9  1‏
919 ‎‡a  routinehiv1genotypingasatooltoidentifydualinfections‏ ‎‡A  Routine HIV-1 genotyping as a tool to identify dual infections‏ ‎‡9  1‏
919 ‎‡a  phenotypicandgenotypiccomparisonsofccr5andcxcr4tropichumanimmunodeficiencyvirustype1biologicalclonesisolatedfromsubtype100infectedindividuals‏ ‎‡A  Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals‏ ‎‡9  1‏
919 ‎‡a  performanceofvidisca454infecessuspensionsandserum‏ ‎‡A  Performance of VIDISCA-454 in feces-suspensions and serum‏ ‎‡9  1‏
919 ‎‡a  novelreplicationincompetentvectorderivedfromadenovirustype11ad11forvaccinationandgenetherapylowseroprevalenceandnoncrossreactivitywithad5‏ ‎‡A  Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.‏ ‎‡9  1‏
919 ‎‡a  novelreplicationincompetentvectorderivedfromadenovirustype11‏ ‎‡A  Novel replication-incompetent vector derived from adenovirus type 11‏ ‎‡9  1‏
919 ‎‡a  multipletransmissionsofastablehumanleucocyteantigenb27cytotoxictcellescapestrainofhiv1inthenetherlands‏ ‎‡A  Multiple transmissions of a stable human leucocyte antigen-B27 cytotoxic T-cell-escape strain of HIV-1 in The Netherlands‏ ‎‡9  1‏
919 ‎‡a  modestnonadherencetoantiretroviraltherapypromotesresidualhiv1replicationintheabsenceofvirologicalreboundinplasma‏ ‎‡A  Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma‏ ‎‡9  1‏
919 ‎‡a  modestdeviationsfromoptimaladherencetoantiretroviraltherapypromoteresidualhiv1replicationintheabsenceofvirologicalreboundinplasma‏ ‎‡A  Modest deviations from optimal adherence to antiretroviral therapy promote residual HIV-1 replication in the absence of virological rebound in plasma.‏ ‎‡9  1‏
919 ‎‡a  majordeclineofhepatitis100virusincidencerateover2decadesinacohortofdrugusers‏ ‎‡A  Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users‏ ‎‡9  1‏
919 ‎‡a  lackofdetectionofxmrvinseminalplasmafromhiv1infectedmeninthenetherlands‏ ‎‡A  Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands‏ ‎‡9  1‏
919 ‎‡a  increasedmultinucleosidedrugresistanceanddecreasedreplicativecapacityofahumanimmunodeficiencyvirustype1variantwithan8aminoacidinsertinthereversetranscriptase‏ ‎‡A  Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase‏ ‎‡9  1‏
919 ‎‡a  incidenceofhumanimmunodeficiencyvirustype1dualinfectionsinamsterdamthenetherlandsduring2003‏ ‎‡A  Incidence of human immunodeficiency virus type 1 dual infections in Amsterdam, The Netherlands, during 2003-2007.‏ ‎‡9  1‏
919 ‎‡a  identificationofalternativeaminoacidsubstitutionsindrugresistantvariantsofthehiv1reversetranscriptase‏ ‎‡A  Identification of alternative amino acid substitutions in drug-resistant variants of the HIV-1 reverse transcriptase‏ ‎‡9  1‏
919 ‎‡a  identificationofanewgenotypeoftorquetenominivirus‏ ‎‡A  Identification of a new genotype of Torque Teno Mini virus‏ ‎‡9  1‏
919 ‎‡a  humanimmunodeficiencyvirustype1gp120envelopecharacteristicsassociatedwithdiseaseprogressiondifferinfamilymembersinfectedwithgeneticallysimilarviruses‏ ‎‡A  Human immunodeficiency virus type 1 gp120 envelope characteristics associated with disease progression differ in family members infected with genetically similar viruses‏ ‎‡9  1‏
919 ‎‡a  hivrnalevelsintransmissionsourcesonlyweaklypredictplasmaviralloadinrecipients‏ ‎‡A  HIV RNA levels in transmission sources only weakly predict plasma viral load in recipients‏ ‎‡9  1‏
919 ‎‡a  hiv1dualinfectionisassociatedwithfastercd4+tcelldeclineinacohortofmenwithprimaryhivinfection‏ ‎‡A  HIV-1 dual infection is associated with faster CD4+T cell decline in a cohort of men with primary HIV infection.‏ ‎‡9  2‏
919 ‎‡a  highlysensitivemethodsbasedonseminestedrealtimereversetranscriptionpcrforquantitationofhumanimmunodeficiencyvirustype1unsplicedandmultiplysplicedrnaandproviraldna‏ ‎‡A  Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA.‏ ‎‡9  1‏
919 ‎‡a  highprevalenceofhepatitisbvirusdualinfectionwithgenotypesaandginhiv1infectedmeninamsterdamthenetherlandsduring2000‏ ‎‡A  High prevalence of hepatitis B virus dual infection with genotypes A and G in HIV-1 infected men in Amsterdam, the Netherlands, during 2000-2011‏ ‎‡9  1‏
919 ‎‡a  highcurrentcd4+tcellcountpredictssuboptimaladherencetoantiretroviraltherapy‏ ‎‡A  High Current CD4+ T Cell Count Predicts Suboptimal Adherence to Antiretroviral Therapy‏ ‎‡9  1‏
919 ‎‡a  hastherateofcd4cellcountdeclinebeforeinitiationofantiretroviraltherapychangedoverthecourseofthedutchhivepidemicamongmsm‏ ‎‡A  Has the rate of CD4 cell count decline before initiation of antiretroviral therapy changed over the course of the Dutch HIV epidemic among MSM?‏ ‎‡9  1‏
919 ‎‡a  fromclinicalsampletocompletegenomecomparingmethodsfortheextractionofhiv1rnaforhighthroughputdeepsequencing‏ ‎‡A  From clinical sample to complete genome: Comparing methods for the extraction of HIV-1 RNA for high-throughput deep sequencing‏ ‎‡9  1‏
919 ‎‡a  easyandaccuratereconstructionofwholehivgenomesfromshortreadsequencedata‏ ‎‡A  Easy and Accurate Reconstruction of Whole HIV Genomes from Short-Read Sequence Data‏ ‎‡9  1‏
919 ‎‡a  differencesinhivtype1rnaplasmaloadprofileofcloselyrelatedcocirculatingethiopiansubtype100strains100and100‏ ‎‡A  Differences in HIV Type 1 RNA Plasma Load Profile of Closely Related Cocirculating Ethiopian Subtype C Strains: C and C′‏ ‎‡9  1‏
919 ‎‡a  dendriticcellspotentlypurgelatenthiv1beyondtcrstimulationactivatingthepi3kaktmtorpathway‏ ‎‡A  Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathway‏ ‎‡9  1‏
919 ‎‡a  correctionviralgeneticvariationaccountsfora3ofvariabilityinhiv1setpointviralloadineurope‏ ‎‡A  Correction: Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe‏ ‎‡9  1‏
943 ‎‡a  202x‏ ‎‡A  2022‏ ‎‡9  1‏
943 ‎‡a  201x‏ ‎‡A  2013‏ ‎‡9  3‏
943 ‎‡a  200x‏ ‎‡A  2007‏ ‎‡9  1‏
946 ‎‡a  a‏ ‎‡9  1‏
996 ‎‡2  PLWABN|9811297018405606‏
996 ‎‡2  ISNI|000000039267299X‏
996 ‎‡2  ISNI|0000000388438420‏
996 ‎‡2  RERO|A002962292‏
996 ‎‡2  RERO|A002962291‏
996 ‎‡2  ISNI|0000000388692170‏
996 ‎‡2  LC|n 79146362‏
996 ‎‡2  NTA|43174503X‏
996 ‎‡2  NTA|208122915‏
996 ‎‡2  NTA|138470715‏
996 ‎‡2  NTA|068612486‏
996 ‎‡2  ISNI|0000000389752518‏
996 ‎‡2  NTA|071709886‏
996 ‎‡2  LC|n 93020157‏
996 ‎‡2  RERO|A006243948‏
996 ‎‡2  ISNI|0000000387789771‏
996 ‎‡2  NTA|071194878‏
996 ‎‡2  ISNI|0000000388222179‏
996 ‎‡2  NTA|308187334‏
996 ‎‡2  SUDOC|114170150‏
996 ‎‡2  ISNI|0000000389226411‏
996 ‎‡2  ISNI|0000000388211533‏
996 ‎‡2  NTA|099594390‏
996 ‎‡2  SUDOC|240695585‏
996 ‎‡2  NTA|099674866‏
996 ‎‡2  RERO|A006087936‏
996 ‎‡2  NTA|070499586‏
996 ‎‡2  ISNI|000000038762917X‏
996 ‎‡2  NTA|289759641‏
996 ‎‡2  NTA|256547483‏
996 ‎‡2  ISNI|0000000067640724‏
996 ‎‡2  NTA|070940967‏
996 ‎‡2  NTA|072408871‏
996 ‎‡2  LC|n 86008832‏
996 ‎‡2  NTA|298814838‏
996 ‎‡2  ISNI|0000000392958832‏
996 ‎‡2  NTA|314075909‏
996 ‎‡2  NTA|364154462‏
996 ‎‡2  ISNI|000000039168290X‏
996 ‎‡2  NTA|091363136‏
996 ‎‡2  ISNI|0000000394131003‏
996 ‎‡2  NTA|42133603X‏
996 ‎‡2  ISNI|0000000393124477‏
996 ‎‡2  NTA|337807841‏
996 ‎‡2  NTA|068334699‏
996 ‎‡2  ISNI|0000000388952462‏
996 ‎‡2  ISNI|0000000393840123‏
996 ‎‡2  NTA|197567746‏
996 ‎‡2  ISNI|0000000392935032‏
996 ‎‡2  NTA|163127557‏
996 ‎‡2  NTA|288671570‏
996 ‎‡2  NTA|298202158‏
996 ‎‡2  NTA|344697185‏
996 ‎‡2  LC|n 92072308‏
996 ‎‡2  DNB|1236657209‏
996 ‎‡2  NTA|287724794‏
996 ‎‡2  NTA|151293333‏
996 ‎‡2  NTA|413587940‏
996 ‎‡2  SUDOC|253474140‏
996 ‎‡2  NTA|274163268‏
996 ‎‡2  ISNI|0000000397172759‏
996 ‎‡2  ISNI|0000000390007611‏
996 ‎‡2  ISNI|0000000468082831‏
996 ‎‡2  ISNI|0000000392866508‏
996 ‎‡2  ISNI|0000000393204311‏
996 ‎‡2  ISNI|0000000384599606‏
996 ‎‡2  NTA|073057428‏
996 ‎‡2  SUDOC|198335687‏
996 ‎‡2  RERO|A016267730‏
996 ‎‡2  ISNI|0000000390585454‏
996 ‎‡2  NTA|39385499X‏
996 ‎‡2  DNB|127810870‏
996 ‎‡2  NTA|186877285‏
996 ‎‡2  NTA|314656731‏
996 ‎‡2  NTA|298814943‏
996 ‎‡2  ISNI|0000000391045134‏
996 ‎‡2  ISNI|0000000395702672‏
996 ‎‡2  BIBSYS|8012128‏
996 ‎‡2  NTA|071854460‏
996 ‎‡2  BNF|16669337‏
996 ‎‡2  BAV|495_314275‏
996 ‎‡2  ISNI|0000000025511676‏
996 ‎‡2  NTA|242336973‏
996 ‎‡2  NTA|101307675‏
996 ‎‡2  NTA|071362916‏
996 ‎‡2  ISNI|000000039464065X‏
996 ‎‡2  NTA|364154705‏
996 ‎‡2  NTA|314621296‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏